-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] Biomedicine has long-term positive fundamentals, and potential new technologies and fields will continue to be favored by the capital market.
In recent years, China's biomedical industry is developing rapidly
.
According to data from the National Bureau of Statistics, in 2020, the market size of China's biopharmaceutical industry will increase by 8.
51% year-on-year to 3.
57 trillion yuan
.
It is estimated that the market size of China's biopharmaceutical industry will exceed 4 trillion yuan in 2022
.
The biological industry is known as the "eternal sunrise industry".
While treating diseases, it is also a symbol of scientific and technological strength and talents
.
Whether at the national or social level, biomedicine has been placed in a higher position
.
For example, in March 2021, the state issued the "14th Five-Year Plan" for the biomedical industry, in which the main focus is to promote technological innovation and high-quality development
.
At the same time, the society has shown a high enthusiasm for investment in the industry, and the R&D investment and financing scale have continued to grow rapidly
.
According to public data, in the past 2021, the total investment and financing in the biomedical field increased by 26% year-on-year, reaching 111.
358 billion yuan
.
With the increasing attention of biopharmaceuticals, as well as the continuous breakthrough of domestic biotechnology, the gradual adjustment of the industrial structure, and the rising per capita disposable income of residents, the domestic biopharmaceutical industry has a strong development momentum
.
Data shows that in the context of an aging population, the demand for biomedicine is showing explosive growth
.
Among them, in 2021, the per capita health care consumption expenditure of national residents will increase by 14.
8% year-on-year to 2,115 yuan, accounting for 8.
8% of the per capita consumption expenditure
.
However, analysts pointed out that while domestic biomedicine is developing rapidly, it is also facing more challenges, such as intensified competition in the industry market
.
It is understood that in recent years, with the rapid development of the biopharmaceutical market and the continuous improvement of capital attention, many companies have entered the field of biopharmaceuticals one after another.
At present, the concentration of the biopharmaceutical industry in the domestic market is relatively low, in order to gain more market share , domestic and foreign enterprises will compete fiercely in technology, product, market and other aspects
.
In the future, more companies will enter the biomedical field, and the industry market will face greater competition
.
Some analysts pointed out that, from the current point of view, although the number of biopharmaceuticals in China is large, the scale is small, the investment in research and development is limited, and the innovation ability is insufficient
.
Among them, many domestic small and medium-sized enterprises mainly rely on the agency of foreign brand reagent products, and local enterprises with independent research and development capabilities and patented technologies are relatively scarce
.
According to the "2020 China Patent Survey Report", among the 735 interviewed universities and 381 interviewed scientific research units, the implementation rates of valid invention patents were 14.
7% and 28.
9%, respectively
.
In order to better promote the development of the domestic biopharmaceutical industry, domestic enterprises need to further increase their R&D investment and enhance their independent innovation capabilities
.
Although the domestic biopharmaceutical industry is still facing the risks of low R&D investment, shortage of professional and technical personnel and intensified competition, the biopharmaceutical industry will usher in huge industry development with the strong support of national policies and the expansion of market demand.
The domestic biopharmaceutical industry will also continue to change
.
For pharmaceutical companies with strong R&D strength and rich R&D pipelines, they are bound to seize more market share
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
In recent years, China's biomedical industry is developing rapidly
.
According to data from the National Bureau of Statistics, in 2020, the market size of China's biopharmaceutical industry will increase by 8.
51% year-on-year to 3.
57 trillion yuan
.
It is estimated that the market size of China's biopharmaceutical industry will exceed 4 trillion yuan in 2022
.
The biological industry is known as the "eternal sunrise industry".
While treating diseases, it is also a symbol of scientific and technological strength and talents
.
Whether at the national or social level, biomedicine has been placed in a higher position
.
For example, in March 2021, the state issued the "14th Five-Year Plan" for the biomedical industry, in which the main focus is to promote technological innovation and high-quality development
.
At the same time, the society has shown a high enthusiasm for investment in the industry, and the R&D investment and financing scale have continued to grow rapidly
.
According to public data, in the past 2021, the total investment and financing in the biomedical field increased by 26% year-on-year, reaching 111.
358 billion yuan
.
With the increasing attention of biopharmaceuticals, as well as the continuous breakthrough of domestic biotechnology, the gradual adjustment of the industrial structure, and the rising per capita disposable income of residents, the domestic biopharmaceutical industry has a strong development momentum
.
Data shows that in the context of an aging population, the demand for biomedicine is showing explosive growth
.
Among them, in 2021, the per capita health care consumption expenditure of national residents will increase by 14.
8% year-on-year to 2,115 yuan, accounting for 8.
8% of the per capita consumption expenditure
.
However, analysts pointed out that while domestic biomedicine is developing rapidly, it is also facing more challenges, such as intensified competition in the industry market
.
It is understood that in recent years, with the rapid development of the biopharmaceutical market and the continuous improvement of capital attention, many companies have entered the field of biopharmaceuticals one after another.
At present, the concentration of the biopharmaceutical industry in the domestic market is relatively low, in order to gain more market share , domestic and foreign enterprises will compete fiercely in technology, product, market and other aspects
.
In the future, more companies will enter the biomedical field, and the industry market will face greater competition
.
Some analysts pointed out that, from the current point of view, although the number of biopharmaceuticals in China is large, the scale is small, the investment in research and development is limited, and the innovation ability is insufficient
.
Among them, many domestic small and medium-sized enterprises mainly rely on the agency of foreign brand reagent products, and local enterprises with independent research and development capabilities and patented technologies are relatively scarce
.
According to the "2020 China Patent Survey Report", among the 735 interviewed universities and 381 interviewed scientific research units, the implementation rates of valid invention patents were 14.
7% and 28.
9%, respectively
.
In order to better promote the development of the domestic biopharmaceutical industry, domestic enterprises need to further increase their R&D investment and enhance their independent innovation capabilities
.
Although the domestic biopharmaceutical industry is still facing the risks of low R&D investment, shortage of professional and technical personnel and intensified competition, the biopharmaceutical industry will usher in huge industry development with the strong support of national policies and the expansion of market demand.
The domestic biopharmaceutical industry will also continue to change
.
For pharmaceutical companies with strong R&D strength and rich R&D pipelines, they are bound to seize more market share
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
